CutisPharma, a Wilmington, Mass.-based developer of “value-added kits” for the compounding pharmacy market, raised an undisclosed amount of venture capital and debt funding.
Ampersand Capital Partners made the investment while Silicon Valley Bank provided a senior credit facility from. In conjunction with the financing, two Ampersand partners, Eric Lev and David Parker, joined CutisPharma’s Board of Directors.
The company intends to use the funds to continue to grow operations.
Founded in 1998 by Indu Muni, Ph.D., Chairman & CEO, CutisPharma develops and commercializes unit-of-use kits to aid pharmacists with the preparation of compounded prescriptions utilized in retail and hospital pharmacies across the United States by physicians, pharmacists, and patients.